Kranenburg A R, de Boer W I, Alagappan V K T, Sterk P J, Sharma H S
Department of Pharmacology, Erasmus MC, University Medical Center, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands.
Thorax. 2005 Feb;60(2):106-13. doi: 10.1136/thx.2004.023986.
Ongoing inflammatory processes resulting in airway and vascular remodelling characterise chronic obstructive pulmonary disease (COPD). Vascular endothelial growth factor (VEGF) and its receptors VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) could play a role in tissue remodelling and angiogenesis in COPD.
The cellular expression pattern of VEGF, Flt-1, and KDR/Flk-1 was examined by immunohistochemistry in central and peripheral lung tissues obtained from ex-smokers with COPD (forced expiratory volume in 1 second (FEV(1)) <75% predicted; n = 14) or without COPD (FEV(1) >85% predicted; n = 14). The immunohistochemical staining of each molecule was quantified using a visual scoring method with grades ranging from 0 (no) to 3 (intense).
VEGF, Flt-1, and KDR/Flk-1 immunostaining was localised in vascular and airway smooth muscle (VSM and ASM) cells, bronchial, bronchiolar and alveolar epithelium, and macrophages. Pulmonary endothelial cells expressed Flt-1 and KDR/Flk-1 abundantly but not VEGF. Bronchial VEGF expression was higher in microvascular VSM cells and ASM cells of patients with COPD than in patients without COPD (1.7 and 1.6-fold, p<0.01, respectively). VEGF expression in intimal and medial VSM (1.7 and 1.3-fold, p<0.05) of peripheral pulmonary arteries associated with the bronchiolar airways was more intense in COPD, as was VEGF expression in the small pulmonary vessels in the alveolar region (1.5 and 1.7-fold, p<0.02). In patients with COPD, KDR/Flk-1 expression was enhanced in endothelial cells and in intimal and medial VSM (1.3, 1.9 and 1.5-fold, p<0.02) while endothelial Flt-1 expression was 1.7 times higher (p<0.03). VEGF expression was significantly increased in bronchiolar and alveolar epithelium as well as in bronchiolar macrophages (1.5-fold, p<0.001). The expression of VEGF in bronchial VSM and mucosal microvessels as well as bronchiolar epithelium was inversely correlated with FEV(1) (r<-0.45; p<0.01).
VEGF and its receptors Flt-1 and KDR/Flk-1 may be involved in peripheral vascular and airway remodelling processes in an autocrine and/or paracrine manner. This system may also be associated with epithelial cell viability during airway wall remodelling in COPD.
导致气道和血管重塑的持续炎症过程是慢性阻塞性肺疾病(COPD)的特征。血管内皮生长因子(VEGF)及其受体VEGFR-1(Flt-1)和VEGFR-2(KDR/Flk-1)可能在COPD的组织重塑和血管生成中起作用。
采用免疫组织化学方法检测从患有COPD(第1秒用力呼气量(FEV(1))<预测值的75%;n = 14)或无COPD(FEV(1)>预测值的85%;n = 14)的戒烟者获取的中央和外周肺组织中VEGF、Flt-1和KDR/Flk-1的细胞表达模式。使用视觉评分法对每个分子的免疫组织化学染色进行定量,评分范围为0(无)至3(强)。
VEGF、Flt-1和KDR/Flk-1免疫染色定位于血管和气道平滑肌(VSM和ASM)细胞、支气管、细支气管和肺泡上皮以及巨噬细胞。肺内皮细胞大量表达Flt-1和KDR/Flk-1,但不表达VEGF。COPD患者支气管VEGF在微血管VSM细胞和ASM细胞中的表达高于无COPD患者(分别为1.7倍和1.6倍,p<0.01)。与细支气管气道相关的外周肺动脉内膜和中膜VSM中VEGF的表达(分别为1.7倍和1.3倍,p<0.05)在COPD中更强,肺泡区域小肺血管中VEGF的表达也是如此(分别为1.5倍和1.7倍,p<0.02)。在COPD患者中,KDR/Flk-1在内皮细胞以及内膜和中膜VSM中的表达增强(分别为1.3倍、1.9倍和1.5倍,p<0.02),而内皮Flt-1的表达高1.7倍(p<0.03)。细支气管和肺泡上皮以及细支气管巨噬细胞中VEGF的表达显著增加(1.5倍,p<0.001)。支气管VSM、黏膜微血管以及细支气管上皮中VEGF的表达与FEV(1)呈负相关(r<-0.45;p<0.01)。
VEGF及其受体Flt-1和KDR/Flk-1可能以自分泌和/或旁分泌方式参与外周血管和气道重塑过程。该系统也可能与COPD气道壁重塑过程中的上皮细胞活力有关。